FDA Authorizes 30 Nicotine Pouches as Altria-PMI-Patent Wars Reshape the $9.9B Global Pouch Market

Published: August 11, 2026 • Category: Industry Analysis • Reading time: 11 min

FDA authorizes four new on! nicotine pouches, bringing the authorized U.S. total to 30 products in August 2026.

The U.S. nicotine pouch market just hit a regulatory milestone that will reshape competitive dynamics for years. On August 4, the FDA authorized four new on! products — Rich Berry 2 mg, Cappuccino 2 mg and 4 mg, and Autumn Spice 2 mg — bringing the total number of FDA-authorized nicotine pouches to 30. All 30 remain concentrated in the hands of just two corporate families: Philip Morris International (via Swedish Match) and Altria Group (via Helix Innovations). Meanwhile, a wave of patent disputes between Altria, Juul, BAT, and Japan Tobacco is redefining who controls the intellectual property underneath this rapidly growing $9.9 billion global category.

FDA Authorizes Four New on! Products: The Flavor Expansion Begins

The August 4 authorization is more than a routine product decision. It represents the first time the FDA has authorized flavored nicotine pouches under the PMTA pathway, following the January 2025 authorization of 20 ZYN products and the June 2026 ZYN modified-risk claim authorization. The new on! products mark a turning point: the nicotine pouch category is moving from mint-and-tobacco basics into the flavor diversification that drives consumer adoption.

Helix Innovations, Altria’s oral nicotine operating company, now holds 10 of the 30 authorized pouch products. The FDA said its evaluation found these four products contain “lower levels of most harmful and potentially harmful constituents” compared to other oral and smokeless tobacco products, with many constituents present at levels too low to be quantified.

The agency emphasized that the authorizations apply only to the four named products. They do not mean the products are safe, nor do they authorize Helix to market them with modified-risk claims. But the regulatory pathway itself is accelerating: the FDA launched its nicotine pouch pilot in September 2025, and lessons from the pilot are now being applied to all nicotine pouch PMTAs across the industry.

Patent wars intensify across the nicotine pouch and vaping technology sectors as IP battles reshape competitive dynamics.

The Patent Wars: Who Owns the Technology Behind the Pouch Boom?

The nicotine pouch category may be growing fast, but the technology underneath it is increasingly contested. Three major patent disputes in July and August 2026 illustrate how intellectual property is becoming the competitive battlefield for the next phase of the smoke-free transition.

Altria vs. Juul: ITC Limits Primary Patent Theory

The U.S. International Trade Commission upheld an administrative law judge’s ruling on August 6 that prevents Altria from advancing its central patent infringement theory against Juul Labs. The ITC found Altria failed to properly disclose its primary infringement argument during early discovery, violating procedural rules. While the ruling strips Altria of its strongest legal weapon, the case continues on remaining patent assertions — meaning the dispute over vaping technology patents remains very much alive.

BAT vs. Japan Tobacco: European Patent Revoked

In a separate ruling, European Patent Office authorities revoked a Japan Tobacco vape patent following a successful challenge by British American Tobacco. The patent covered cartridge designs featuring visual status displays for e-liquid levels. BAT argued the concept lacked novelty and an inventive step, and the EPO agreed after finding the design had been disclosed in prior patent applications. The ruling reflects the intensifying IP competition among major tobacco companies as they fight to protect hardware differentiation in a category where product innovation moves fast.

BAT vs. VPR Brands: $14.9M Settlement Secures Auto-Draw Rights

R.J. Reynolds Vapor (BAT subsidiary) and VPR Brands settled their patent dispute through a $14.9 million licensing deal in July. VPR granted BAT a non-exclusive, worldwide, perpetual license for its foundational auto-draw/buttonless e-cigarette hardware patent (U.S. Patent No. 8,205,622 B2). The settlement shields BAT’s Vuse product line from future patent challenges on auto-draw activation technology. Notably, VPR Brands gained industry notoriety for securing a federal injunction against Elf Bar vapes in the U.S. — a case that forced Elf Bar’s parent company to pay $5.25 million to buy back U.S. trademark rights earlier in 2026.

“As competition intensifies across vaping, heated tobacco, and nicotine pouch technologies, intellectual property has become an increasingly important strategic weapon. The question is not just who makes the best product, but who owns the rights to make it.”
— Tobacco Insider, Patent Wars Chronology, August 2026

The global nicotine pouch market reaches $9.9 billion in 2026, growing at 19.4% CAGR toward $56.7 billion by 2035.

The $9.9 Billion Global Pouch Market: Growth, Share, and Regional Dynamics

Behind these regulatory and legal battles sits a market growing at a pace that rivals the early days of e-cigarettes. According to Global Market Insights (March 2026), the global nicotine pouch market is valued at $9.9 billion in 2026, growing at a compound annual rate of 19.4% through 2035. At that trajectory, the category will quintuple within a decade — reaching an estimated $56.7 billion by 2035.

U.S. Market: Nicotine Pouches Now 53% of Smokeless

The structural shift inside the U.S. smokeless tobacco category is accelerating. According to Circana data for the 52 weeks ending March 2026, total smokeless tobacco dollar sales reached $13.0 billion — a 13.1% increase. But the growth is entirely concentrated in modern oral nicotine pouches, which surged 29.5% in dollar sales to $6.89 billion, capturing 52.9% of the total smokeless category. Unit sales for pouches jumped 29.2% to 1.10 billion units.

Traditional formats are heading in the opposite direction. Moist snuff dollar sales slipped 0.8% to $5.99 billion, with unit sales plummeting 8.0%. Chewing tobacco fell 9.7% to $142 million. The price per unit of snuff rose 7.8% to $8.39, reflecting manufacturers leaning into pricing power to offset volume losses. That pricing leverage will eventually run out as pouches continue to take share.

FDA-authorized nicotine products increasingly dominate US retail shelf space as enforcement priorities shift.

Altria’s Oral Nicotine Inflection: From Underdog to Challenger

One of the most underappreciated shifts in the nicotine pouch landscape is Altria’s rapid rise. The company shipped over 46 million on! cans in Q1 2026 alone — an 18% increase — while on! PLUS achieved a retail footprint of approximately 100,000 stores covering 85% of category volume within six weeks of its March launch.

The FDA pilot program authorization gave on! PLUS a structural regulatory advantage. As the first and only oral nicotine pouch authorized under the pilot, it carries differentiated status that could accelerate future PMTA decisions. Altria has filed additional flavor submissions pending FDA review, which would further expand its authorized portfolio against ZYN’s broader but less diversified 20-product lineup.

“Oral nicotine pouches drove an estimated 9.5 percentage point increase in total oral tobacco industry volume over the past six months, with the category gaining 9.1 share points to exceed 58% of total oral tobacco. This is not just Altria’s story — it is a structural shift in how consumers access nicotine.”
— Altria Q1 2026 Earnings Analysis, aInvest

But the competitive landscape is tightening. ZYN’s growth has decelerated from 12.7% over the trailing 52 weeks to approximately negative 1% in the most recent four-week period, per NielsenIQ data. The slowdown reflects intense competition from BAT’s VELO Plus moist pouches, which have driven BAT’s U.S. oral nicotine market share from 6.7% in 2024 to 16.2% in 2025. PMI is responding with the ZYN Ultra range, designed to reinvigorate growth with higher-strength, moisture-slim pouch formulations.

FDA Enforcement Shift: The Real Game-Changer for Retail

Underpinning all of these developments is a regulatory shift that does not get enough attention. The FDA’s May 2026 guidance on enforcement priorities for unauthorized tobacco products effectively opened the U.S. market to a new generation of smoke-free products. Under the new framework, the agency generally will not prioritize enforcement against unauthorized products if the manufacturer has a pending PMTA that has been accepted and filed for scientific review.

The practical effect: companies with pending applications can now sell their newest products while navigating the regulatory pipeline, rather than competing with older-generation devices. For retailers, this provides a clearer stocking framework. The FDA plans to publish a public-facing list of manufacturers and products falling within the enforcement policy — a transparency measure the National Association of Tobacco Outlets has long advocated for.

This guidance is already reshaping investor valuations. Tobacco companies generating 20% or more of revenue from vapes and nicotine pouches are being re-rated from dividend plays to growth stocks. PMI trades at 21 times expected earnings, a 70% premium to Altria and BAT, both near 12x. BAT, which now generates nearly a fifth of global revenue from smoke-free products — the same threshold PMI crossed in 2019 — could see its valuation separate from Altria if the re-rating pattern holds.

Closing Outlook: Three Converging Forces

The nicotine pouch market in August 2026 is shaped by three forces converging simultaneously:

First, regulatory acceleration. The FDA has authorized 30 pouches, is applying pilot efficiencies to all PMTAs, and has opened enforcement discretion for pending applications. The regulatory bottleneck is easing, and the pace of authorizations will accelerate.

Second, IP warfare. Patent disputes between Altria, Juul, BAT, and Japan Tobacco are defining the competitive moat. Companies that secure IP positions — whether through litigation victories (BAT’s EPO win), settlements (BAT-VPR $14.9M deal), or discovery rules (Altria-Juul ITC) — will shape who manufactures and distributes the next generation of nicotine delivery products.

Third, market math. At $9.9 billion and growing at 19.4% annually, nicotine pouches represent the fastest-growing segment in the global nicotine industry. The category has captured majority share of U.S. smokeless tobacco in under five years. The winners will be companies that combine regulatory access (FDA authorization), intellectual property protection (patent portfolios), and distribution scale (retail footprint).

For investors, the near-term catalysts are clear: additional FDA flavor authorizations (Altria’s pending on! filings), the Altria-Juul ITC final determination, and Q3 earnings data showing whether ZYN Ultra and VELO Plus can sustain their momentum. For supply chain executives, the message is straightforward: the nicotine pouch category is no longer nascent. It is mainstream, regulated, and growing fast enough to reshape the entire tobacco industry value chain.